Abstract. Recent evidence shows that altered microRNA-126 (miR-126) expression is implicated in the progression of colorectal cancer (CRC). However, the precise roles and mechanisms of miR-126 in CRC remain unclear. The aim of this study was to investigate the roles of miR-126 in CRC cells and to elucidate miR-126-mediated mechanisms in CRC cells. First, miR-126 expression was analyzed using qRT-PCR in 4 human CRC cell lines (SW480, SW620, HT-29 and HCT-116). Furthermore, the biological properties of miR-126 in CRC cells in vitro were examined by applying Cell Counting Kit 8, cell cycle, cell apoptosis and transwell assays. The mechanisms and pathways of miR-126-mediated in CRC cells were detected by using qRT-PCR, western blotting and luciferase reporter assay. We found that miR-126 overexpression inhibited cell proliferation, migration and invasion, and induced cell arrest in the G0/ G1 phase of CRC cells, suggesting that miR-126 functions as a tumor suppressor in CRC cells. Furthermore, we identified the CXC chemokine receptor 4 (CXCR4) as a target of miR-126, and showed that it was negatively regulated by miR-126. We demonstrated that miR-126-mediated tumor suppression might be partly dependent on AKT and ERK1/2 signaling pathways. In conclusion, our data revealed that miR-126 functions as a tumor suppressor in CRC cells by regulating CXCR4 expression via the AKT and ERK1/2 signaling pathways and might be a novel target for therapeutic strategies in CRC.
Introduction
Colorectal cancer (CRC) is the third most common malignancy and the third leading cause of cancer-related mortality among men and women in the United States (1) . It is estimated that there is a total of 142,820 new cancer cases diagnosed and 50,830 CRC deaths in 2013, accounting for 9% of all cancer deaths (1) . Despite the improvement of multimodal anticancer strategies, the prognosis of advanced CRC is very poor, with 5-year survival rates for stage III and stage IV colon cancer of 65.4 and 12.8%, respectively (2) . Thus, it is critically important to further explore the molecular pathogenesis of CRC, which may provide new targets for diagnosis and treatment.
MicroRNAs (miRs) are a type of non-coding, endogenous, small RNAs with a length of approximately 23 nucleotides that can regulate gene expression at the post-transcriptional level through binding to the 3' untranslated region (3'-UTR) of the target mRNA, subsequently triggering either translational repression or mRNA cleavage (3, 4) . Growing evidence suggests that miRs are associated with a wide array of biological processes, including metabolism, development, cell proliferation, differentiation and apoptosis (5) . To date, miR dysregulation has been described in numerous malignancies (6) (7) (8) (9) . These abnormal miRs are involved in cancer development, acting as tumor suppressors or oncogenes by negatively regulating their targets (10) .
In this way, several miRs are involved in cell proliferation, migration, invasion, and poor disease prognosis of CRC, including miR-126. MiR-126 has been reported frequently to be downregulated in human cancers and may function as a tumor suppressor (11) (12) (13) . It has been revealed that miR-126 targets IRS1, VEGF, p85β, and some other molecules to inhibit cancer growth (14) (15) (16) . Moreover, some studies have shown that miR-126 acts as negative regulator of tumor invasion and metastasis in cancers (12, 17, 18) . However, the precise roles and mechanisms of miR-126 in CRC remain to be elucidated.
In this study, we confirmed that miR-126 acts as a tumor suppressor in CRC cells, by inhibiting cell proliferation, migration, and invasion, and inducing G0/G1 phase arrest. Furthermore, we found that miR-126 targets CXC chemokine receptor 4 (CXCR4) and we explored the underlying mecha- 
Materials and methods
Cell culture and reagents. The CRC cell lines SW480, SW620, HT-29, and HCT-116 were routinely cultured in RPMI-1640 medium (Gibco, USA) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin at 37˚C in a humidified air atmosphere containing 5% CO 2 . Exponentially growing cells were used for experiments. MiR-126 mimic, miR-126 negative control mimic (NC mimic), miR-126 inhibitor, and miR-126 negative control inhibitor (NC inhibitor) were purchased from Ribobio (RiboBio Co. Ltd., China). qRT-PCR analysis of mRNA and miRNA expression. For miRNA and mRNA analyses, total RNA was isolated from cells using TRIzol reagent (Invitrogen). qRT-PCR was performed using SYBR ® Premix Ex Taq™ II (Takara, Japan) according to the manufacturer's protocol. The expression of miR-126 and CXCR4 mRNA was normalized to U6 and β-actin, respectively. The 2 -∆CT method was used for analysis. Forward miRNA and mRNA primers were synthesized by Sangon Biotech (Shanghai, China) and the sequences of the primers used were as follows: miR-126, 5'-tcgtaccgtgagtaataatgcg-3' (forward); U6, 5'-ctcgcttcggcagcaca-3' (forward); universal qRT-RCR primer, the One Step PrimeScript ® miRNA cDNA Synthesis kit (Takara) (reverse); CXCR4, 5'-ttgtcatcctgtcctgctattg-3' (forward), 5'-tgttctcaaactcacacccttg-3' (reverse); β-actin, 5'-ggc ggcaacaccatgtaccct-3' (forward) and 5'-aggggccggactcgtcat act-3' (reverse).
Cell viability assay. A total of 3x10 3 SW480 and HT-29 cells per well were plated in 96-well plates for 24 h and then transfected with miR-126 mimic or NC mimic. Cell viability was measured at 48 h post-transfection using CCK8 assay according to the manufacturer's instructions. The absorbance was determined at 450 nm.
Cell cycle and apoptosis assay. At 48 or 72 h post-transfection with miR-126 mimic or NC mimic, SW480 and HT-29 cells were trypsinized. For cell cycle assay, the cells were fixed with 70% ethanol at 4˚C overnight, then treated with RNase A (50 µg/ml), stained with PI (50 µg/ml) (Beyotime, China) for 30 min and subjected to flow cytometry. For apoptosis assay, the cells were resuspended in binding buffer containing Annexin V-FITC and PI (Beyotime) according to the manufacturer's instructions. Apoptosis was analyzed by flow cytometry. Annexin V-FITC-positive and PI-negative cells were observed to undergo apoptosis.
Migration and invasion assay. SW480 and SW620 cells were used at 48 h post-transfection with miR-126 mimic or NC mimic. A 24-well transwell plate (8-µm pore size; Corning Costar, USA) was used to measure migratory and invasive ability in vitro. For migration assay, 2x10 5 cells were plated in the top chamber with a non-coated membrane. For invasion assay, 3x10 5 cells were seeded in the top chamber coated with Matrigel (BD Biosciences, USA). In both assays, cells were suspended in serum-free medium, and the lower chamber was filled with RPMI-1640 containing 20% fetal bovine serum. After incubation at 37˚C for 24 h, non-migratory cells on the upper surface were removed using a cotton swab, then fixed in methanol and stained with 0.1% crystal violet (Beyotime). Five random fields were analyzed for each insert at x100 magnification under a microscope.
Construction of luciferase reporter vectors and luciferase
reporter assay. DNA fragments of the 3'-UTRs of CXCR4 mRNA (RefSeq NM_001008540) containing the putative binding sites of miR-126 were synthesized. The fragments were then subcloned into the XhoI and NotI sites downstream of the Renilla luciferase coding region in the psiCHECK-2 vector (Promega, USA), and validated by sequencing by Sangon Biotech. The reporter plasmids with wild-type 3'-UTR or mutated 3'-UTR were named as PsiCHECK2-CXCR4-wt or PsiCHECK2-CXCR4-mut, respectively. SW480 cells were plated at 1x10 5 cells/well on 24-well plates and co-transfected with PsiCHECK2-CXCR4-3'-UTR (psi-CXCR4), PsiCHECK2-mutCXCR4-3'-UTR (psi-CXCR4-mut), or empty vector plasmid and miR using Lipofectamine 2000. Cells were harvested at 48 h post-transfection, and Firefly and Renilla luciferase activities were analyzed using the Dual-Luciferase Report assay (Promega) according to the manufacturer's instructions.
Western blotting. Total cellular proteins were lysed using RIPA buffer (Beyotime). Equivalent amounts of protein were resolved by 10% SDS-PACE gel, transferred onto PVDF membranes (Millipore, USA), and incubated with antibodies to CXCR4 (Abcam, UK), AKT (pan), phospho-AKT (Ser473), ERK1/2, or phospho-ERK1/2 (Cell Signaling Technology, USA) at 4˚C overnight. The protein bands were then incubated with horseradish peroxidase-conjugated antibodies (Beyotime) and visualized using ECL. GADPH was used as a loading control.
Statistical analysis.
All experiments were performed in triplicate. Data are expressed as the means ± SD. Differences between groups were calculated with one-way ANOVA and Student's t-test. Differences were considered significant at P<0.05.
Results
MiR-126 expression in CRC cell lines. qRT-PCR was performed to evaluate miR-126 levels in 4 CRC cell lines (SW480, SW620, HT-29 and HCT-116). As shown in Fig. 1 , miR-126 expression was downregulated in CRC cell lines and might be involved in CRC development.
MiR-126 inhibits cell proliferation, and induces G0/G1 arrest of CRC cells.
To determine the roles of miR-126 in CRC cells, we adopted CCK8 assay, cell cycle, and apoptosis assay to evaluate the biological properties of miR-126. The results of CCK8 assay implied that cell viability was significantly impaired by miR-126 mimic as compared to NC mimic ( Fig. 2A) . In addition, in the cell cycle distribution analysis, we found that miR-126 overexpression enhanced the proportion of cells in the G0/G1 phase compared with NC mimic (Fig. 2B  and C) . However, miR-126 had little effect on the apoptosis rate (Fig. 3) . Based on these data, we conclude that miR-126 mimic inhibits cell proliferation, and induces G0/G1 phase arrest, but does not affect the apoptosis of CRC cells.
MiR-126 suppresses cell migration and invasion of CRC cells in vitro.
To elucidate the involvement of miR-126 in migration and invasion, the transwell assay was employed to evaluate the migration and invasion capacity of CRC cells. We found that miR-126 overexpression inhibited cell migration (Fig. 4A  and B) . The results of the invasion assay revealed that the number of invaded cells was reduced when cells were treated with miR-126 mimic (Fig. 4C and D) . Overall, these data show that miR-126 overexpression suppresses the migration and invasion capacity of CRC cells.
CXCR4 is a target of miR-126. By using bioinformatic analysis tools, i.e., MicroCosm Targets (http://www.ebi. ac.uk/enright-srv/microcosm/htdocs/targets/v5/) and PicTar (http://pictar.mdc-berlin.de/), we sought to predict a putative binding sites of miR-126 that are located at bases 239-245nt of the CXCR4 3'-UTR (Fig. 5A) . To further confirm whether CXCR4 is a direct target of miR-126, the luciferase reporter vectors of the CXCR4 3'-UTR or its mutation containing miR-126 binding sites were constructed. Co-transfection was performed with miR-126 mimic (or NC mimic), psi-CXCR4 (or psi-CXCR4-mut, or empty vector) plasmids into SW480 cells, the dual-luciferase reporter assay was used to determine the reporter activities of the different constructs. We observed that the luciferase activity of psi-CXCR4 was repressed by miR-126 mimic as compared with control (Fig. 5B) . Moreover, miR-126 mimic reduced CXCR4 protein level, while miR-126 inhibitor enhanced CXCR4 protein expression (Fig. 7) . These results demonstrate that CXCR4 may be a direct target of miR-126.
MiR-126 negatively regulates CXCR4 expression at the posttranscriptional level.
To explore the modulation of CXCR4 expression by miR-126, western blot and qRT-PCR analyses were carried out in SW480 and SW620 cells. MiR-126 level was markedly elevated in cells transfected with miR-126 mimic compared to NC mimic (Fig. 6A) . Western blot analyses revealed that the increase in miR-126 expression resulted in a decrease in the CXCR4 protein level (Fig. 7) . On the contrary, transfection with miR-126 inhibitor reduced miR-126 expression (Fig. 6A) , which increased the CXCR4 protein level (Fig. 7) . However, unlike the CXCR4 protein expression, CXCR4 mRNA level remained unaltered with regard to miR-126 level (Fig. 6B) . Our results indicate that miR-126 negatively regulates CXCR4 expression at the posttranscriptional level.
Effects of miR-126 on AKT and ERK1/2 signaling pathways.
To determine whether there were some changes in AKT and ERK1/2 signaling pathways in miR-126-transfected cells, we examined the phosphorylation status of AKT and ERK1/2 by western blotting. We found that miR-126 overexpression led to decreased levels of phosphorylated AKT and ERK1/2 (Fig. 8A) , while transfection with miR-126 inhibitor elevated the expression of phosphorylated AKT and ERK1/2 (Fig. 8B) . However, there was no difference in the levels of total AKT and ERK1/2 with regard to miR-126 (Fig. 8) . These data suggest that miR-126 may be an important regulator in the AKT and ERK1/2 signaling pathways.
Discussion
Aberrant expression of miR-126 has been reported to be involved in human tumor development. However, the roles and mechanisms of miR-126 in CRC remain largely unknown. In this study, we focused on miR-126.
Previous studies have indicated that miR-126 is frequently downregulated in various cancers (9, (11) (12) (13) . MiR-126 has also been shown to be downregulated in CRC (11, 14, 19) . Recently, accumulating evidence has demonstrated that miR-126 is a tumor-suppressive miRNA in several malignancies. MiR-126 has been shown to inhibit cancer cell proliferation and induce G0/G1 arrest by targeting IRS1, SLC7A5 and VEGF (15, 16, 20) . Moreover, miR-126 has been demonstrated to inhibit tumor invasion and metastasis in breast and pancreatic cancer (12, 17, 18) . MiR-126 has also been reported to suppress CRC cell growth, migration and invasion (14, 21) by regulating certain targets. According to these studies, miR-126 functions as a tumor suppressor in tumor development. However, it is still controversial as to whether miR-126 is a tumor suppressive or oncogenic miRNA. For instance, it was reported that miR-126 inhibits apoptosis, increases the viability of AML cells, and enhances the colony-forming ability of mouse normal bone marrow progenitor cells alone through targeting Polo-like kinase 2 (22) . Furthermore, some studies demonstrated that miR-126 contributes to angiogenesis by targeting Spred-1 and PIK3R2, which are negative regulators of the vascular endothelial growth factor pathway (23, 24) . Moreover, miR-126 was found to inhibit SOX2 expression and further contribute to gastric carcinogenesis (25) . In view of these different reports, it is indispensable to further investigate the roles of miR-126 in regulating the biological properties of CRC cells in vitro.
In this study, we found that endogenous miR-126 expression was downregulated in CRC cell lines, implying that miR-126 may participate in CRC carcinogenesis. In addition, our results showed that miR-126 overexpression suppressed cell proliferation, and induced cell cycle arrest in G0/G1 phase, but did not affect apoptosis of CRC cells. Furthermore, we confirmed that restoration of miR-126 expression could weaken migration and invasion capability of CRC cells in vitro. These observations are in agreement with most previous reports, suggesting that miR-126 acts as a tumor suppressor in CRC cells and is a potential target for the therapeutics intervention of CRC.
To clarify possible mechanisms of miR-126-mediated tumor-suppression in CRC cells, we performed bioinformatics analyses to identify candidate target genes of miR-126. Due to the crucial roles of CXCR4 in human cancers, CXCR4 was chosen as a potential target of miR-126 for further research. CXCR4, the receptor for chemokine CXCL12 (26) , is known to be widely expressed in various types of human cancers, including CRC. Several studies have established that CXCR4 plays a key role in tumor initiation, progression, metastasis and survival in CRC (27, 28) . However, how CXCR4 mediates these processes has not been elucidated clearly. It has previously been shown that CXCR4 expression was regulated by some miRNAs, e.g., by miR-146a in Kaposi's sarcoma-associated herpesvirus (29) , by miR-150 in bone marrow-derived mononuclear cells (30) , and by miR-146a to control megakaryopoiesis (31) . We demonstrated that CXCR4 protein expression decreased in CRC cells by transfection with miR-126 mimic, and increased by transfection with miR-126 inhibitor. In contrast, CXCR4 mRNA levels in CRC cells were unaltered with regard to miR-126 expression. These findings suggest a miR-126-mediated post-transcriptional regulatory mechanism. Moreover, we confirmed that CXCR4 might be a direct target of miR-126 by dual-luciferase reporter assay. From these data, we conclude that CXCR4 is negatively regulated by miR-126, which may explain, at least in part, the tumorsuppressive effects of miR-126 in CRC cells. Certainly, there are other potential mechanisms accounting for miR-126-mediated tumor suppression of CRC, e.g., other targets of miR-126 and other regulators of miR-126. Furthermore, the regulation of CXCR4 expression by miR-126 might not be as prominent as some other mechanisms in CRC.
It has been suggested that AKT and ERK are downstream targets of CXCR4 signal transduction (32, 33) . Shen et al showed that CXCR4-induced proliferation was mediated by AKT and ERK signaling in human pancreatic cancer cells (34) . Brand et al reported that CXCR4-mediated homing and CRC cell migration may be highly dependent on AKT and ERK signaling (35) . On the basis of these reports, we wanted to find out whether miR-126-mediated tumor suppression depends on AKT or ERK1/2 signaling pathways via regulating CXCR4 expression. As expected, miR-126 restoration reduced the expression of phosphorylated AKT and ERK1/2, whereas miR-126 inhibitor increased the levels of phosphorylated AKT and ERK1/2, without altering total AKT and ERK1/2 protein levels. These data indicate that miR-126 might be an important regulator in AKT and ERK1/2 signaling. Moreover, it is possible that modulation of the CXCR4 expression by miR-126 resulted in the subsequent regulation of AKT and ERK1/2 phosphorylation. Hence, we propose that miR-126-induced tumor suppression may be mediated by modulation of CXCR4 via AKT and ERK1/2 signaling pathways. However, the complex mechanisms of miR-126-mediated tumor suppression need to be further elucidated.
In conclusion, our data suggest that miR-126 functions as a tumor suppressor in CRC cells, by inhibiting cell proliferation, migration, and invasion and inducing cell arrest in the G0/G1 phase, but not by affecting cell apoptosis. Moreover, miR-126-mediated tumor suppression may, in part, depend on the regulation of CXCR4 via AKT and ERK1/2 signaling pathways. Therefore, miR-126 could be a diagnostic as well as therapeutic target for CRC therapy.
